Identification of Promising Lead Compounds from Capsicum annuum Targeting BACE-1 for Alzheimer’s Disease Therapy: A Molecular Docking Study

Year : 2023 | Volume :01 | Issue : 01 | Page : 40-49
By

Aisiri Vijayasimha

Samiksha Bhor

  1. Student Department of Bioinformatics, BioNome Private Limited Karnataka India
  2. Bioinformatics Associate Department of Bioinformatics, BioNome Private Limited Karnataka India

Abstract

Background: Alzheimer’s disease (AD) is a neurodegenerative disorder affecting millions of people worldwide. Beta-secretase 1 (BACE-1) is an important therapeutic target for AD treatment. Capsicum annuum (CA) is a commonly consumed plant with potential neuroprotective properties. In this study, we aimed to identify potential lead compounds from CA that can target BACE-1 for AD therapy using molecular docking. Methods: A library of 15 compounds from CA was obtained from PubChem, and their structures were optimized using PyRx-v0.8. BACE-1 protein structure was obtained from the Protein Data Bank (PDB). Docking simulations were performed using PyRx-v0.8, and the results were analyzed using BIOVIA Discovery Studio 2019. Results: Among the studied 15 ligands, the best binding affinity was shown by 6 compounds. Capsaicin, Dihydrocapsaicin, Apigenin, Riboflavin, Quercetin, and Luteolin had a binding affinity of -6.4, -8.4, -8.4, -8.5, and -8.7 kcal/mol respectively. Luteolin had the highest binding score of -8.7 kcal/mol, this indicates its best possible inhibitory action with BACE-1. Conclusion: Our study identified Dihydrocapsaicin, and Capsaicin from CA as promising lead compounds that can target BACE-1 for AD therapy. Further in vitro and in vivo studies are needed to validate their therapeutic potential.

Keywords: Alzheimer’s disease, Capsicum annuum, BACE-1, molecular docking

[This article belongs to International Journal of Genetic Modifications and Recombinations(ijgmr)]

How to cite this article: Aisiri Vijayasimha, Samiksha Bhor. Identification of Promising Lead Compounds from Capsicum annuum Targeting BACE-1 for Alzheimer’s Disease Therapy: A Molecular Docking Study. International Journal of Genetic Modifications and Recombinations. 2023; 01(01):40-49.
How to cite this URL: Aisiri Vijayasimha, Samiksha Bhor. Identification of Promising Lead Compounds from Capsicum annuum Targeting BACE-1 for Alzheimer’s Disease Therapy: A Molecular Docking Study. International Journal of Genetic Modifications and Recombinations. 2023; 01(01):40-49. Available from: https://journals.stmjournals.com/ijgmr/article=2023/view=111664

Browse Figures

References

  1. Sharma S. Alzheimer’s disease: Causes, treatment & basic science review. IP Int J Compr Adv Pharmacol [Internet]. 2021;6(3):108–16. Available from: http://dx.doi.org/10.18231/ijcap.2021.020
  2. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health [Internet]. 2022;7(2):e105–25. Available from: http://dx.doi.org/10.1016/S2468-2667(21)00249-8
  3. Atri A. Current and future treatments in Alzheimer’s disease. Semin Neurol [Internet]. 2019;39(2):227–40. Available from: http://dx.doi.org/10.1055/s-0039-1678581
  4. Hampel H, Vassar R, De Strooper B, Hardy J, Willem M, Singh N, et al. The β-secretase BACE1 in Alzheimer’s disease. Biol Psychiatry [Internet]. 2021;89(8):745–56. Available from: http://dx.doi.org/10.1016/j.biopsych.2020.02.001
  5. Geerts H, Grossberg GT. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer’s disease. J Clin Pharmacol [Internet]. 2006;46(7 Suppl 1):8S-16S. Available from: http://dx.doi.org/
    1177/0091270006288734
  6. Exploring the pathogenesis of Alzheimer’s disease in basal forebrain cholinergic neurons: Converging insights from alternative hypotheses.
  7. Akram M, Nawaz A. Effects of medicinal plants on Alzheimer’s disease and memory deficits. Neural Regen Res [Internet]. 2017;12(4):660–70. Available from: http://dx.doi.org/10.4103/1673-5374.205108
  8. Thuphairo K, Sornchan P, Suttisansanee U. Bioactive compounds, antioxidant activity and inhibition of key enzymes relevant to Alzheimer’s disease from sweet pepper (Capsicum annuum) extracts. Prev Nutr Food Sci [Internet]. 2019;24(3):327–37. Available from: http://dx.doi.org/10.3746/pnf.2019.24.3.327
  9. Bakrim S, Aboulaghras S, El Menyiy N, El Omari N, Assaggaf H, Lee L-H, et al. Phytochemical compounds and nanoparticles as phytochemical delivery systems for Alzheimer’s disease management. Molecules [Internet]. 2022;27(24):9043. Available from: http://dx.doi.org/10.3390/molecules27249043
  10. IMPPAT: A curated database of Indian Medicinal Plants, Phytochemistry And Therapeutics, Karthikeyan Mohanraj#, Bagavathy Shanmugam Karthikeyan#, R.P. Vivek-Ananth#, R.P. Bharath Chand, S.R. Aparna, P. Mangalapandi and Areejit Samal*, Scientific Reports 8:4329 (2018).
  11. Vassar R, Kandalepas PC. The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer’s disease. Alzheimers Res Ther [Internet]. 2011;3(3):20. Available from: http://dx.doi.org/10.1186/alzrt82
  12. Jabir NR, Rehman MT, Alsolami K, Shakil S, Zughaibi TA, Alserihi RF, et al. Concatenation of molecular docking and molecular simulation of BACE-1, γ-secretase targeted ligands: in pursuit of Alzheimer’s treatment. Ann Med [Internet]. 2021;53(1):2332–44. Available from: http://dx.doi.org/10.1080/07853890.2021.2009124
  13. Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, Mendiondo MS, et al. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles “do count” when staging disease severity: Neuritic plaques and neurofibrillary tangles “do count” when staging disease severity. J Neuropathol Exp Neurol [Internet].2007;66(12):1136–46.Availablefrom: http://dx.doi.org/10.1097/nen.0b013e31815c5efb
  14. Rodriguez RD, Molina M, Leite RP, Sabadin R, Takada LT, Suemoto CK, et al. P1‐359: Neuropathological findings of an early‐onset dementia case with atypical Alzheimer’s disease: How challenging can the clinical diagnosis of mixed ad be? Alzheimers Dement [Internet]. 2018;14(7S_Part_8):P432–P432. Available from: http://dx.doi.org/10.1016/j.jalz.2018.06.367
  15. Kadry H, Noorani B, Cucullo L. A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS [Internet]. 2020;17(1):69. Available from: http://dx.doi.org/10.1186/s12987-020-00230-3
  16. Piccialli I, Tedeschi V, Caputo L, D’Errico S, Ciccone R, De Feo V, et al. Exploring the therapeutic potential of phytochemicals in Alzheimer’s disease: Focus on polyphenols and monoterpenes. Front Pharmacol [Internet]. 2022;13:876614. Available from: http://dx.doi.org/10.3389/
    2022.876614
  17. Marashly ET, Bohlega SA. Riboflavin has neuroprotective potential: Focus on Parkinson’s disease and migraine. Front Neurol [Internet]. 2017;8:333. Available from: http://dx.doi.org/10.3389/
    2017.00333
  18. Dihydrocapsaicin Attenuates Blood Brain Barrier and Cerebral Damage in Focal Cerebral Ischemia/Reperfusion via Oxidative Stress and Inflammatory Adchara Janyou1, Piyawadee Wicha1.
  19. Pegorini S, Braida D, Verzoni C, Guerini-Rocco C, Consalez GG, Croci L, et al. Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbils. Br J Pharmacol [Internet]. 2005;144(5):727–35. Available from: http://dx.doi.org/10.1038/
    bjp.0706115
Regular Issue Subscription Original Research
Volume 01
Issue 01
Received April 13, 2023
Accepted May 6, 2023
Published June 28, 2023
Views: 442